Get health information you can use, fact-checked by Nebraska Medicine experts.

Patient Stories Craig Johnson, MD, Nuclear Medicine (right), and Beth McCaw, lead nuclear medicine technologist (center), administer the initial PLUVICTO dose to Phil Painter (left).

New prostate cancer treatment provides hope
When Phil Painter learned he had stage 4 prostate cancer last year, he wasn’t sure what the future would hold. A PET/CT scan revealed he would be the perfect candidate for a new FDA-approved prostate cancer treatment called PLUVICTO. In August, he became the first Nebraska Medicine patient to receive this treatment.
Subscribe to Advancing Health